Tau PET in Imaging and Cognition: Healthy Adults From 55-90
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03372317|
Recruitment Status : Recruiting
First Posted : December 13, 2017
Last Update Posted : February 11, 2022
|Condition or disease||Intervention/treatment|
|Mild Cognitive Impairment Aging||Drug: 18F-MK-6240|
Many cognitively healthy older adults have, upon post mortem evaluations, been found to have varying amounts of neurofibrillary tangles (tau) and beta-amyloid plaque deposits, which are the hallmark brain pathologies known to be associated with Alzheimer's disease and various other dementias. While some with these pathologies may not clinically express cognitive decline or dementia in their lifetime, human post-mortem studies suggest that increasing neurofibrillary tangle density correlates with neurodegeneration and cognitive impairment.
Imaging tauopathy in-vivo provides an opportunity to examine neurocognitive correlates of differential levels of tauopathy in the brain, allowing to further qualify pre-clinical states of cognitive impairment. The investigators aim to investigate possible protective mechanisms, such as cognitive reserve, that may modulate the relationship between tauopathy and cognitive decline.
|Study Type :||Observational|
|Estimated Enrollment :||105 participants|
|Official Title:||Tau Positron Emission Tomography (PET) in Imaging and Cognition|
|Actual Study Start Date :||June 1, 2018|
|Estimated Primary Completion Date :||January 2023|
|Estimated Study Completion Date :||December 2023|
Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
Results of the 18F-MK-6240 PET scan will be correlated with other observations.
Other Name: 6-[18F]Fluoro-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine
- Total number of individuals with tau present [ Time Frame: Up to 5 years ]Based on the scans, the total number of subjects with identifiable tau in their scans will be measured.
- Cognition [ Time Frame: Up to 5 years ]Relation of Tau PET to measures of cognition such as memory and reasoning
- Functional imaging (fMRI) [ Time Frame: Up to 5 years ]Relation of Tau PET to imaging acquired during task performance
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03372317
|Contact: Reshma Babukuttyfirstname.lastname@example.org|
|United States, New York|
|Columbia University Medical Center||Recruiting|
|New York, New York, United States, 10032|
|Contact: Ashley Mensing, BS 212-305-6314 email@example.com|
|Principal Investigator: Yaakov Stern, PhD|
|Principal Investigator:||Yaakov Stern, PhD||Columbia University|